1 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Nextech VIII Carry SCSPFiled to raise in 2024, with no closing reported yet. | 2024 | Indefinite | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
1 partner is named across this firm’s filings, 1 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Jakob Loven | Quiet | Biotech & pharma | 6 | 0 |
Classified sectors of Nextech Viii Carry Scsp’s own portfolio companies, based on 6 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Nextech Viii Carry Scsp’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| The Column Group | 2 | A2 Biotherapeutics, Hexagon Bio |
| Vida Ventures | 2 | A2 Biotherapeutics, IconOVir Bio |
| ARCH Venture Partners | 1 | Vividion Therapeutics |
| Versant Vantage |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| 1 |
| Vividion Therapeutics |
| Versant Venture Capital | 1 | Vividion Therapeutics |
| Versant Venture V AIV | 1 | Vividion Therapeutics |
| Versant Voyageurs | 1 | Vividion Therapeutics |
A shared board seat: a company where filings name a Nextech Viii Carry Scsp partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
